Drug Trial Radar · NCT07318883
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Jan 2031
Study completion Jan 2031
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab and chemotherapy as first-line treatment in patients with sqNSCLC. Part II is a randomized, double-blind, multicenter, parallel-controlled phase III clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy as first-line treatment in patients with sqNSCLC.
Conditions
- Squamous NSCLC
Interventions
HLX07Drug
Intravenous infusion (IV), once every 3 weeks (Day 1 of each cycle \[D1\]).
HLX07 placeboDrug
Intravenous infusion (IV), once every 3 weeks (Day 1 of each cycle \[D1\]).
SerplulimabDrug
IV, once every 3 weeks (D1).
PembrolizumabDrug
IV, once every 3 weeks (D1).
CarboplatinDrug
IV, once every 3 weeks (D1).
Paclitaxel or Nab-PaclitaxelDrug
Paclitaxel: IV, once every 3 weeks (D1). Nab-paclitaxel: IV, once every 3 weeks (D1, 8, 15).
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR assessed by BICR (part I)Time frame: Assessed up to appoximately 6 months from enrollment
- PFS assessed by BICR (part I)Time frame: Assessed up to appoximately 16 months from enrollment
- PFS assessed by BICR (part II)Time frame: Assessed up to appoximately 23 months from enrollment
- OS (part II)Time frame: Assessed up to appoximately 42 months from enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.